Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158

The primary objectives of this study are:

- To acquire data for the development of one-day rest/stress cardiac PET perfusion
imaging protocols for BMS747158 with comparable diagnostic image quality to a two-day
rest/stress PET protocol

- To assess the safety of multiple doses of BMS747158

The secondary objectives of this study are:

- To assess PET imaging parameters and image quality following administration of
BMS747158 at rest and at stress (pharmacologic or exercise) same day (at different time
intervals) and 16-48 hours after the rest injection

- To assess feasibility of gated cardiac PET imaging with BMS747158 for left ventricular
function assessment

- To assess agreement of one and two day rest/stress PET imaging with BMS747158 in
patients with reversible ischemia with rest/stress single photon emission computed
tomography (SPECT) imaging

- To perform a preliminary assessment of the diagnostic accuracy of one-day and two-day
rest/stress PET perfusion imaging with BMS747158 as compared with invasive coronary
angiography or computed tomography angiography (CTA) for detection of

Inclusion Criteria:

- Provide signed IC prior to undergoing any study procedures

- Be male or nonpregnant female, between the ages of 18 to 75 years, inclusive

- Have:A rest/stress SPECT imaging study (either exercise or pharmacologic stress)
within 21 days of enrollment, using 99mTc-labeled tracers and showing reversible
ischemia

- Female patients must:

- be nonlactating,

- no longer have child-bearing potential, either because they are post-menopausal
(defined as amenorrhea ≥ 12 consecutive months, or because they have undergone
successful surgical sterilization (hysterectomy, bilateral tubal ligation or
bilateral oophorectomy)

Exclusion Criteria:

- Presence of any condition that may disrupt and/or increase permeability of the BBB,
including multiple sclerosis, Alzheimer's disease, Parkinson's disease, acute central
nervous system (CNS) infection, CNS tumor, autoimmune disease affecting the CNS, or
CNS inflammatory

- Current significant illness, pathology or physical examination or vital signs
measurement-findings that could potentiate any adverse pharmacological event
associated with a vasodilatory drug or any pathology that, in the opinion of the
investigator, might confound the interpretation of the results of the study

- Known hypersensitivity to adenosine, dipyridamole or aminophylline

- Presence of any contraindications to exercise stress testing

- History of New York Heart Association Class III or IV Congestive Heart Failure (CHF)

- Any major surgery within 4 weeks prior to enrollment or planned within 2 weeks
following completion of the 2-week telephone follow-up assessment

- Inability to tolerate IV medication.

- History of drug or alcohol abuse within the last year

- Participation in any investigational drug, device, or placebo study within 6 months
prior to study enrollment